Advances In Chemistry Enable Next-Generation Targeted Bioconjugates: Considerations For Development And Manufacturing

By Francisco Velazquez, Ph.D. Sr. Director of Chemistry at Abzena

Chemistry innovation is transforming targeted bioconjugates into modular systems, expanding payload repertoires beyond traditional microtubule inhibitors to include topoisomerase inhibitors, immune agonists, targeted protein degraders, and oligonucleotides. Advanced linkers and site-specific conjugation technologies—such as engineered cysteines, disulfide re-bridging, and enzymatic processes—enable greater product homogeneity, narrower drug-antibody ratios, and more predictable pharmacokinetic profiles. However, these sophisticated architectures introduce significant analytical and large-scale manufacturing challenges, including increased aggregation risks, complex purification demands, and higher production costs. To successfully translate scientific breakthroughs into reliable medicines, discovery and development teams must intertwine manufacturing strategies as early as the discovery phase, balancing therapeutic potency with scalability and economic sustainability.

Explore how integrated chemistry and early manufacturing strategies can optimize your next-generation conjugate programs today.